Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667924 | PMC |
| http://dx.doi.org/10.3389/fphar.2023.1305705 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Buschke-Lowenstein tumour.
BMJ Case Rep
January 2025
Department of Dermatology, Venereology and Leprosy, BLDE Deemed to be University, Vijayapura, Karnataka, India
Concerns regarding the systematic review and editorial on oral dutasteride for frontal fibrosing alopecia.
J Eur Acad Dermatol Venereol
January 2025
Inflammatory Immune-Mediated Chronic Skin Diseases Laboratory, IMIBIC, Córdoba, Spain.
[Diabetes and the skin : Associations often not adequately considered].
Dermatologie (Heidelb)
January 2025
Abteilungen für Dermatologie, Venerologie, Allergologie und Immunologie, Dessau Medical Center, Brandenburg Medizinische Hochschule Theodor Fontane, Auenweg 38, 06847, Dessau, Deutschland.
Liver parasites: A global endemic and journey from infestation to intervention.
World J Gastroenterol
January 2025
Department of Medicine, Section of Gastroenterology, Aga Khan University Hospital, Karachi 75500, Sindh, Pakistan.
Parasites have coexisted with humans throughout history, forming either symbiotic relationships or causing significant morbidity and mortality. The liver is particularly vulnerable to parasitic infections, which can reside in, pass through, or be transported to the liver, leading to severe damage. This editorial explores various parasites that infect the liver, their clinical implications, and diagnostic considerations, as discussed in the article "Parasites of the liver: A global problem?".
View Article and Find Full Text PDFArticle Synopsis
- Ruxolitinib cream, shown to be safe and effective in a phase 3 study, has demonstrated its anti-inflammatory and itch-relieving properties in children aged 2-11 with mild to moderate atopic dermatitis (AD).
- The study focused on assessing safety, tolerability, pharmacokinetics, and quality of life while using the cream at maximum levels over longer periods, with 29 children participating and applying the cream twice daily for 4 weeks, followed by individualized usage.
- Results indicated that 31% of participants experienced treatment-related adverse events, but no severe health issues arose, and significant improvements in skin condition and quality of life were sustained for up to 52 weeks.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!